After a very tough first half of FY24, Fusion appears to be seeing some signs of the hoped-for turnaround in trading, helped by its decision to broaden its client base from biopharma into the adjacent sectors of veterinary drugs and diagnostics. This has been seen in the form of rising month on month revenue that allowed it to be broadly cash neutral in October. However, given its cash reach that extends into FY25, an upturn in the second half is crucial to the investment case. Recently reported ....
13 Dec 2023
Allenby Capital: Fusion Antibodies - Interims
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Allenby Capital: Fusion Antibodies - Interims
Fusion Antibodies Plc (FAB:LON) | 3.2 0 (-9.2%) | Mkt Cap: 3.08m
- Published:
13 Dec 2023 -
Author:
Robin Davison | John Savin -
Pages:
4
After a very tough first half of FY24, Fusion appears to be seeing some signs of the hoped-for turnaround in trading, helped by its decision to broaden its client base from biopharma into the adjacent sectors of veterinary drugs and diagnostics. This has been seen in the form of rising month on month revenue that allowed it to be broadly cash neutral in October. However, given its cash reach that extends into FY25, an upturn in the second half is crucial to the investment case. Recently reported ....